Advice
Following SMC collaboration with NICE on MTA TA878: nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19:
nirmatrelvir and ritonavir (Paxlovid®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
SMC restriction:
Patients who have an increased risk for progression to severe COVID-19, as defined in section 5 of NICE final guidance.
Download detailed advice250KB (PDF)
Medicine details
- Medicine name:
- nirmatrelvir and ritonavir (Paxlovid)
- SMC ID:
- SMC2557
- Indication:
Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Infections
- Submission type
- Collaboration
- Status
- Restricted
- Date advice published
- 01 May 2025